| Authors: |
Berry-Kravis E; Departments of Pediatrics and Neurological Sciences, Rush University Medical Center, Chicago, IL, USA., Hagerman R; Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California-Davis Medical Center, Sacramento, CA, USA.; Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA, USA., Budimirovic D; Departments of Psychiatry and Child Psychiatry, Fragile X Clinic, Kennedy Krieger Institute/the Johns Hopkins Medical Institutions, Baltimore, MD, USA.; Department of Psychiatry & Behavioral Sciences-Child Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, USA., Erickson C; Department of Psychiatry and Behavioral Neuroscience, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, OH, USA., Heussler H; Centre for Clinical Trials in Rare Neurodevelopmental Disorders, Children's Health Queensland, Brisbane, Australia.; Centre for Child Health Research, University of Queensland, Brisbane, Australia., Tartaglia N; Department of Pediatrics, Developmental Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO, USA., Cohen J; Fragile X Alliance Inc, North Caulfield, VIC, Australia.; Centre for Developmental Disability Health Victoria, Monash University, Clayton, VIC, Australia., Tassone F; Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California-Davis Medical Center, Sacramento, CA, USA.; Department of Biochemistry and Molecular Medicine, School of Medicine, University of California-Davis, Sacramento, CA, USA., Dobbins T; The Griesser Group, Conshohocken, PA, USA., Merikle E; Labcorp Drug Development, Durham, NC, USA., Sebree T; Zynerba Pharmaceuticals Inc., Devon, PA, USA., Tich N; Zynerba Pharmaceuticals Inc., Devon, PA, USA., Palumbo JM; Zynerba Pharmaceuticals Inc., Devon, PA, USA., O'Quinn S; Zynerba Pharmaceuticals Inc., Devon, PA, USA. Oquinns@Zynerba.com. |
